List of Excipients in Branded Drug ACARBOSE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aphena Pharma Solutions - Tennessee LLC	ACARBOSE	acarbose	43353-951	CELLULOSE, MICROCRYSTALLINE
Aphena Pharma Solutions - Tennessee LLC	ACARBOSE	acarbose	43353-951	MAGNESIUM STEARATE
Aphena Pharma Solutions - Tennessee LLC	ACARBOSE	acarbose	43353-951	SILICON DIOXIDE
Aphena Pharma Solutions - Tennessee LLC	ACARBOSE	acarbose	43353-951	STARCH, CORN
Alvogen Inc	ACARBOSE	acarbose	47781-340	CELLULOSE, MICROCRYSTALLINE

Generic Drugs Containing ACARBOSE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	acarbose	0054-0140	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	acarbose	0054-0140	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	acarbose	0054-0140	SILICON DIOXIDE
Hikma Pharmaceuticals USA Inc	acarbose	0054-0140	STARCH, CORN
Aiping Pharmaceutical	acarbose	11788-039	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in ACARBOSE?

# Of NDCs	Excipient
18	CELLULOSE, MICROCRYSTALLINE
18	MAGNESIUM STEARATE
18	SILICON DIOXIDE
18	STARCH, CORN

Acarbose Excipient Strategy and Commercial Opportunities

Last updated: October 25, 2026

Acarbose is a mature, immediate-release oral antidiabetic with broad generic availability and limited remaining molecule-level exclusivity. Commercial value is concentrated in excipient-enabled differentiation: better tablet disintegration, lower gastrointestinal burden, improved dose flexibility, combination products, and region-specific formulations. The highest-probability opportunities are generic lifecycle products rather than new chemical entity or biosimilar programs.

What is the commercial profile of acarbose?

Acarbose is an oral alpha-glucosidase inhibitor that delays the digestion of dietary carbohydrates in the intestinal lumen. It is administered with the first bite of each meal and is available in 25 mg, 50 mg, and 100 mg strengths in the United States and other markets.[1]

Attribute	Acarbose profile
Active ingredient	Acarbose
Pharmacologic class	Alpha-glucosidase inhibitor
Primary use	Type 2 diabetes
Administration	Oral, with the first bite of each meal
Common strengths	25 mg, 50 mg, 100 mg
Dosage form	Immediate-release tablet
Systemic exposure	Low; activity is primarily gastrointestinal
Main tolerability issue	Flatulence, diarrhea, abdominal discomfort
Regulatory status	Generic small-molecule drug
Biosimilar relevance	None
Main commercial barrier	Modest demand, gastrointestinal adverse effects, established low-cost generics

Acarbose competes with metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and other glucose-lowering therapies. Its clinical use is strongest in markets where low cost, postprandial glucose control, and oral administration are valued. China, parts of Asia, and selected European markets have historically been more important for acarbose than the United States.

Acarbose is not a biologic. Biosimilar regulation does not apply. Competitive entry occurs through conventional generic drug applications, including abbreviated new drug applications in the United States.

What excipients are used in acarbose tablets?

Acarbose immediate-release tablets generally use conventional direct-compression or wet-granulation excipients. The inactive ingredients reported for branded and generic products vary by manufacturer and jurisdiction.

Common excipient classes include:

• Microcrystalline cellulose as a filler and compression aid.
• Corn starch or other starches as a filler and disintegrant.
• Colloidal silicon dioxide as a glidant.
• Magnesium stearate as a lubricant.
• Film-coating polymers, plasticizers, pigments, and opacifiers where a coated tablet is used.

The FDA-approved Precose label identifies conventional tablet excipients, including corn starch, magnesium stearate, microcrystalline cellulose, and colloidal silicon dioxide.[1] Generic products may use different excipient systems, colors, coating materials, and manufacturing processes. Each formulation must satisfy applicable quality, bioequivalence, stability, and inactive-ingredient requirements.

Because acarbose acts locally in the gastrointestinal tract, excipient selection has a different commercial logic from that for a highly absorbed systemic drug. The main targets are tablet performance, dose uniformity, dissolution or dispersion, stability, swallowability, and gastrointestinal tolerability.

Which excipient strategies can improve acarbose tablets?

1. Faster and more consistent disintegration

Acarbose must be present in the intestinal lumen when carbohydrate digestion begins. A tablet that disintegrates slowly or inconsistently could create avoidable variability in local drug availability.

A practical formulation strategy is to use a low-viscosity, robust disintegrant system, such as:

• Crospovidone.
• Croscarmellose sodium.
• Sodium starch glycolate.
• A starch-based disintegrant combined with microcrystalline cellulose.

The formulation must balance disintegration against tablet hardness, friability, lubrication, and moisture sensitivity. Excessive lubricant concentration or prolonged lubrication can reduce wetting and delay tablet breakup.

2. Improved swallowing and dose flexibility

The 100 mg strength can be relatively large for patients taking several tablets daily. Commercial opportunities include:

• Smaller, higher-density tablets.
• Film coatings that reduce surface roughness.
• Scored tablets where permitted by the product design.
• Dispersible or orally disintegrating formats.
• Multiparticulate products filled into capsules or sachets.
• Granules that can be mixed with a small volume of food or liquid, subject to regulatory validation.

Acarbose must be taken with meals. A dosage form that is easier to carry, open, swallow, or administer at mealtimes could improve adherence. An orally disintegrating product would need careful taste masking because acarbose may produce an unpleasant taste profile and has a relatively high dose compared with many highly potent oral drugs.

3. Reduction of gastrointestinal burden

Flatulence, diarrhea, abdominal distension, and abdominal pain are central barriers to acarbose persistence.[1,2] Excipients cannot eliminate the pharmacologic mechanism that produces these effects, but they may support a more controlled and reproducible presentation.

Potential approaches include:

• Controlled particle-size distribution.
• Improved content uniformity.
• Faster dispersion with lower local concentration hotspots.
• Multiparticulate systems designed to distribute the active ingredient across the gastrointestinal contents.
• Low-osmolarity excipient systems.
• Avoidance of unnecessary fermentable excipients.

The commercial claim must remain narrow. A formulation may improve tolerability only if supported by comparative clinical evidence. A change in disintegration or particle size does not automatically establish reduced gastrointestinal adverse events.

4. Moisture and stability control

Acarbose is a complex carbohydrate-derived molecule. Formulators should evaluate hygroscopicity, moisture-mediated changes in powder flow, chemical stability, microbial risk for aqueous systems, and tablet hardness over shelf life.

Relevant excipient controls include:

• Low-moisture grades of microcrystalline cellulose and starch.
• High-barrier blister packaging.
• Desiccant-containing bottles where justified.
• Low-water-content film coatings.
• Silica or other flow aids selected through compatibility studies.
• Avoidance of aqueous processing unless stability data support it.

Moisture protection may be more commercially valuable than a novel excipient because it can improve manufacturing yield and shelf-life robustness across multiple climate zones.

5. Improved manufacturability

Acarbose products are typically low-margin generic medicines. The strongest excipient opportunities are those that lower manufacturing cost or reduce batch failure.

A preferred formulation should provide:

• Consistent flow into the tablet press.
• Low segregation risk across 25 mg, 50 mg, and 100 mg strengths.
• Adequate tensile strength at low compression force.
• Short blending and lubrication times.
• Reliable scale-up from development to commercial equipment.
• Low tablet weight without capping or lamination.
• Stable dissolution after accelerated and long-term storage.

Co-processed excipients may have commercial value if they combine flow, compactibility, and disintegration in a single platform. The patentability of the final product depends on the specific composition, ratios, process parameters, and demonstrated performance.

What formulations are protected by acarbose patents?

The original acarbose molecule and early pharmaceutical development rights are long expired in major markets. Acarbose was first commercialized decades ago, and the standard immediate-release tablet is now a mature generic dosage form.

IP category	Current commercial relevance
Original acarbose compound patents	Expired or commercially exhausted in major markets
Conventional immediate-release tablets	Generally exposed to generic competition
Standard excipient combinations	Usually weak unless narrowly claimed and technically demonstrated
Modified-release systems	Potentially protectable if clinically and technically differentiated
Orally disintegrating or dispersible products	Potential formulation opportunity
Multiparticulate or meal-associated delivery	Potentially protectable, subject to proof
Manufacturing processes	Possible process protection if non-obvious and scalable
Combination products	Potential method-of-use or formulation opportunity
Packaging and moisture-control systems	Usually supporting IP rather than primary exclusivity

A company seeking protection should not rely on a generic claim to "an acarbose tablet comprising an excipient." Stronger claim strategies may include:

• Narrow excipient ratios linked to rapid disintegration.
• Defined particle-size distributions.
• Moisture limits and packaging combinations.
• Specific granulation or compaction processes.
• Multiparticulate architectures.
• Taste-masking systems.
• Coated particles that release acarbose under defined gastrointestinal conditions.
• Formulations supported by reduced gastrointestinal adverse events or improved adherence.

Patent strength will depend on unexpected performance, reproducibility, prior-art distance, and the ability to demonstrate a meaningful advantage over existing generic tablets.

When does acarbose lose exclusivity?

Acarbose lost its primary U.S. market exclusivity many years ago. The FDA approved Precose, the original U.S. branded product, in the 1990s. The commercial market is now generic and price competitive.[1,3]

There is no biosimilar exclusivity timeline because acarbose is a synthetic small molecule. Current commercial protection is more likely to arise from:

• Product-specific formulation patents.
• Method-of-use patents.
• Pediatric or other regulatory exclusivity, if granted for a specific product.
• Trade secrets covering manufacturing or process controls.
• Brand recognition and distribution contracts.

A new acarbose formulation could obtain regulatory approval without receiving meaningful market exclusivity unless it qualifies for a specific statutory exclusivity period or has enforceable patents. A 505(b)(2) route may be relevant for a reformulated product that relies partly on existing acarbose data, but the pathway would depend on the proposed dosage form, clinical claims, and level of reliance on the reference product.[4]

What is the Orange Book status of acarbose?

The FDA Orange Book is the relevant U.S. source for approved drug products, therapeutic-equivalence evaluations, patents, and exclusivity listings.[3] Acarbose products are regulated as conventional prescription tablets. The original branded product and approved generic products are not subject to biologic interchangeability rules.

The key diligence points are:

1. Confirm whether the reference listed drug remains commercially active.
2. Review current therapeutic-equivalence codes for each strength.
3. Check whether any patent or exclusivity information remains listed for a specific product.
4. Review FDA-approved labeling for inactive ingredients.
5. Confirm whether a proposed dosage form can use an ANDA pathway or requires a different application.

Because Orange Book entries can change and individual generic products may differ, patent clearance must be performed against the current FDA listing and the relevant product-specific patents. An old acarbose compound patent is not a meaningful barrier to a new generic launch.

Which companies are challenging acarbose exclusivity?

Acarbose is already challenged by the generic market rather than by a concentrated, high-value Paragraph IV campaign. Multiple manufacturers have supplied acarbose tablets in the United States and international markets.

A Paragraph IV certification would be relevant only if a current Orange Book-listed patent covered the reference product. For a mature acarbose tablet, the primary launch risk is generally not an active compound patent. It is the ordinary risk of ANDA review, manufacturing readiness, product-quality deficiencies, supply interruptions, and commercial pricing.

The most credible competitive threats to a differentiated acarbose product are:

• Low-cost conventional tablets.
• Regional manufacturers with established diabetes distribution.
• Combination products that replace acarbose therapy.
• Newer glucose-lowering drugs with stronger clinical adoption.
• Domestic manufacturers in markets that favor local supply chains.

What patent litigation affects acarbose?

Acarbose has no widely recognized current litigation profile comparable with major branded oncology, immunology, or specialty drugs. The core molecule is mature, and the market has had extensive time for generic entry.

Litigation risk would rise if a company introduced:

• A new extended-release formulation.
• An orally disintegrating product with a proprietary taste-masking system.
• A fixed-dose combination.
• A method-of-use claim for a defined patient population.
• A manufacturing process that materially reduces cost or improves purity.
• A product with clinical evidence linking the formulation to improved tolerability.

For such products, patent disputes would likely focus on obviousness, enablement, written description, claim construction, and whether the alleged formulation benefit is adequately demonstrated.

What are the best commercial opportunities for acarbose excipients?

Generic cost reduction

The most immediate opportunity is a robust, low-cost tablet platform that supports all three strengths. An excipient supplier can sell value through:

• Better flow.
• Lower compression force.
• Reduced rejection rates.
• Faster tableting.
• Improved stability.
• Simplified formulation architecture.

This opportunity is large in unit volume but limited in per-tablet pricing.

Premium adherence-oriented products

A differentiated product could target patients who discontinue acarbose because of swallowing difficulty, dosing inconvenience, or gastrointestinal effects. Candidate formats include:

• Orally disintegrating tablets.
• Dispersible granules.
• Small multiparticulate doses.
• Calendar or meal-linked packaging.
• Low-moisture blister presentations.

The clinical burden for premium positioning is higher. A formulation must show more than acceptable dissolution. It should demonstrate adherence, usability, tolerability, or a clinically meaningful administration advantage.

Combination products

Acarbose could be combined with other oral antidiabetic agents, including metformin or agents used for postprandial control. Combination development faces dose titration, interaction, tolerability, and regulatory complexity. The product may be commercially attractive in markets where acarbose remains commonly prescribed, but the combination must not make dose adjustment more difficult.

Regional dosage forms

Asia-focused development may offer more opportunity than a U.S.-only strategy. Relevant products include smaller tablets, sachets, dispersible granules, and formulations aligned with local meal patterns and distribution channels. Regulatory requirements remain jurisdiction-specific, and excipient acceptability must be assessed against local pharmacopeias and permitted-use lists.

How strong is the acarbose patent estate?

The molecule-level estate is weak because acarbose has been generic for many years. A new formulation estate could be moderate if it includes narrow, technically reproducible claims supported by comparative data.

Estate component	Strength assessment
Original compound	Low
Standard tablet composition	Low
Broad excipient claims	Low
Narrow performance-based formulation claims	Moderate
Novel multiparticulate delivery	Moderate, subject to prior art
Manufacturing process claims	Moderate if process-specific and difficult to design around
Clinical method claims	Variable
Trade secrets	Potentially meaningful for process know-how
Packaging-only claims	Usually limited

Freedom-to-operate work should cover U.S., Europe, China, Japan, India, and major commercial markets. Patent term, national-phase status, maintenance fees, prosecution history, and opposition records must be reviewed separately. A patent that remains formally active in one country may have little commercial impact if the product is not marketed there.

What generic launch scenarios exist for acarbose?

Scenario 1: Conventional generic tablet

This is the lowest-risk pathway. The product uses a conventional excipient system and competes primarily on cost, quality, and supply reliability. The margin profile is likely narrow.

Scenario 2: Improved immediate-release tablet

A better-flowing, faster-disintegrating or smaller tablet may support modest differentiation. The product still faces generic substitution and must prove equivalent performance.

Scenario 3: Patient-convenience dosage form

An orally disintegrating, dispersible, or multiparticulate product could command a higher price if it improves administration. Development and regulatory costs are higher, and taste, dose loading, and stability are technical constraints.

Scenario 4: Combination product

A fixed-dose product may improve convenience but introduces greater regulatory and clinical complexity. It is most attractive where acarbose use is high and the partner drug has a complementary dosing pattern.

Scenario 5: Manufacturing-platform licensing

An excipient supplier or contract development organization could license a tablet platform to several regional acarbose manufacturers. This may produce recurring revenue without carrying the full cost of a branded pharmaceutical launch.

What FDA regulatory issues apply to acarbose excipient innovation?

For a conventional generic tablet, the formulation must meet ANDA requirements, including pharmaceutical equivalence and bioequivalence to the reference listed drug.[4] Changes in excipients may affect dissolution, stability, content uniformity, impurity profile, and manufacturability.

A novel dosage form may require a different regulatory strategy. A 505(b)(2) application could be relevant where the sponsor relies on published literature or FDA findings for acarbose while introducing a new formulation or route-related feature. The application may require additional clinical, pharmacokinetic, usability, or tolerability data.

Excipient selection should also account for:

• FDA inactive-ingredient precedent.
• Compendial quality standards.
• Nitrosamine and elemental-impurity risk where relevant.
• Microbiological quality for aqueous or dispersible systems.
• Food-effect and meal-administration performance.
• Labeling of administration with the first bite of a meal.

Key Takeaways

• Acarbose is a mature generic drug with no meaningful biosimilar pathway.
• The original molecule-level patent estate is commercially weak or expired in major markets.
• Excipient value lies in tablet performance, moisture control, dose flexibility, taste masking, and manufacturing efficiency.
• Gastrointestinal tolerability is the main clinical problem, but excipients can address it only with comparative evidence.
• Conventional generic tablets offer volume but limited margin.
• Orally disintegrating, dispersible, multiparticulate, and combination products offer greater differentiation but carry higher regulatory risk.
• The strongest new patents would claim narrow compositions, manufacturing processes, or demonstrated performance advantages.
• China and other Asian markets may offer stronger commercial potential than the United States for differentiated acarbose products.
• A practical business model is licensing an excipient-enabled manufacturing platform to regional generic manufacturers.

FAQs

Can acarbose be formulated as an orally disintegrating tablet?

Yes, but the high dose, taste profile, tablet mass, and moisture sensitivity create formulation constraints. Taste masking and rapid disintegration must be balanced against dose loading and stability.

Which excipient is best for acarbose disintegration?

No single excipient is universally optimal. Crospovidone, croscarmellose sodium, sodium starch glycolate, and starch-based systems should be screened against hardness, friability, dissolution, moisture, and scale-up performance.

Is an acarbose extended-release product commercially attractive?

Potentially, but the mechanism creates a technical challenge because acarbose must act in the gastrointestinal tract during carbohydrate digestion. Any extended-release concept must demonstrate improved clinical performance rather than merely slower dissolution.

Does acarbose have a biosimilar market?

No. Acarbose is a small-molecule drug and competes through generic drug pathways, not biosimilar approval pathways.

Can an excipient supplier patent an acarbose formulation?

Yes, if the formulation contains a novel and non-obvious composition, process, or performance characteristic. Broad claims covering ordinary fillers, binders, lubricants, or disintegrants are unlikely to provide strong protection without unexpected technical results.

References

1. U.S. Food and Drug Administration. (n.d.). Precose (acarbose) tablets prescribing information. FDA/DailyMed.

2. American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes. Diabetes Care, 47(Supplement 1).

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

4. U.S. Food and Drug Administration. (2017). ANDA submissions: Content and format guidance for industry. FDA.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.